Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1

References

• Jørgensen HG, Holyoake TL. Characterization of cancer stem cells in chronic myeloid leukemia. Biochem Soc Trans 2007;35:1347–1351.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009;16:122–131.
   PubMed Web of Science ®Google Scholar
• Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007;21:3214–3231.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, O’Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054–1061.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Hayette S, Lagarde V, et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 2008;68:9809–9816.
   PubMed Web of Science ®Google Scholar
• Okabe S, Tauchi T, Ohyashiki K. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells. Clin Cancer Res 2008;14:6181–6186.
   PubMed Web of Science ®Google Scholar
• Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009;109:2989–3011.
   PubMed Web of Science ®Google Scholar
• Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008;65:3145–3167.
   PubMed Web of Science ®Google Scholar
• Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA, Scheper RJ. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000;12:550–556.
   PubMed Web of Science ®Google Scholar
• Raaijmakers MH. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. Leukemia 2007;21: 2094–2102.
   PubMed Web of Science ®Google Scholar
• Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007;1775:237–262.
   PubMed Web of Science ®Google Scholar
• Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells:therapeutic implications. Clin Cancer Res 2008;14:3881–3888.
   PubMed Web of Science ®Google Scholar
• Brendel C, Scharenberg C, Dohse M, et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007;21:1267–1275.
   PubMed Web of Science ®Google Scholar
• Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006;108:1370–1373.
   PubMed Web of Science ®Google Scholar
• Melo JV. Imatinib and ABCG2: who controls whom? Blood 2006;108:1116–1117.
   Web of Science ®Google Scholar
• Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739–3745.
   PubMed Web of Science ®Google Scholar
• Burger H, vanTol H, Boersma AW, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;104:2940–2942.
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Germain GS, Harwood FC, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004;64:2333–2337.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Shiozawa K, Hassel BA, Ross DD. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 2006;108:678–684.
   PubMed Web of Science ®Google Scholar
• Carpenter AE, Jones TR, Lamprecht MR, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 2006;7:R100.
   PubMed Web of Science ®Google Scholar
• Lamprecht MR, Sabatini DM, Carpenter AE. CellProfiler: free, versatile software for automated biological image analysis. Biotechniques 2007;42:71–75.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med 2006;125: 93–106.
   PubMedGoogle Scholar
• Baran Y, Ural AU, Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology 2007;12:497–503.
   PubMed Web of Science ®Google Scholar
• Hirayama C, Watanabe H, Nakashima R, et al. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. Pharm Res 2008;25:827–835.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070–1079.
   PubMed Web of Science ®Google Scholar
• Scappini B, Gatto S, Onida F, et al. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer 2004;100:1459–1471.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498–3505.
   PubMed Web of Science ®Google Scholar
• Azzariti A, Porcelli L, Simone GM, et al. Tyrosine kinase inhibitors and multidrug resistance proteins:interactions and biological consequences. Cancer Chemother Pharmacol 2010;65:335–346.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368–2373.
   PubMed Web of Science ®Google Scholar
• Assef Y, Rubio F, Coló G, del Mónaco S, Costas MA, Kotsias BA. Imatinib resistance in multidrug-resistant K562 human leukemic cells. Leuk Res 2009;33:710–716.
   PubMed Web of Science ®Google Scholar
• Munteanu E, Verdier M, Grandjean-Forestier F, et al. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. Biochem Pharmacol 2006; 71:1162–1174.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wu H, Liu X, et al. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008;76:582–588.
   PubMed Web of Science ®Google Scholar
• Burger H, van Tol H, Brok M, et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 2005;4: 747–752.
   PubMed Web of Science ®Google Scholar
• Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008;112:3348–3354.
   PubMed Web of Science ®Google Scholar
• Klawitter J, Zhang YL, Klawitter J, Anderson N, Serkova NJ, Christians U. Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture. Biomed Chromatogr 2009;23:1251–1258.
   PubMed Web of Science ®Google Scholar
• Clark RE, Davies A, Pirmohamed M, Giannoudis A. Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma 2008;49:639–642.
   PubMed Web of Science ®Google Scholar
• Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. hOCT 1 and resistance to imatinib. Blood 2005;106:1133–1134.
   PubMed Web of Science ®Google Scholar
• Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008;83:258–264.
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697–704.
   PubMed Web of Science ®Google Scholar
• Dinis J, Gromicho M, Martins C, Laires A, Rueff J, Rodrigues A. Evaluation of DSBs repair in imatinib resistant cell lines. Haematologica 2009; 94(Suppl. 2): Abstract 130.
   Google Scholar